“There is a notably increasing interest from the scientifc community regarding our genetic precision medicine approach for type 1 diabetes” says Ulf Hannelius, CEO of Diamyd Medical. “The ASHG conference and community provides a strong platform to spread the awareness of our approach to an even wider audience than before, strengthening our position as a company focused on cutting edge science and drug development”.

The ASHG Annual Meeting is the largest human genetics and genomics meeting and exposition in the world. The accepted poster is titled “HLA haplotype determines treatment response to GAD-alum immunotherapy in Type 1 diabetes: An applied example of a genetic precision medicine approach to pivotal clinical trial design”.

Ulf  Hannelius has also been invited to present as an expert speaker at the Bio-Markers for Rare Diseases conference, to be held as a digital event on November 9-10, 2021. As previously announced, Diamyd Medical, represented by Ulf Hannelius, has been elected to present an abstract of the  Diamyd^® meta-analysis results at the EASD diabetes conference, on October 1, 2021. The EASD conference will be held virtually September 27 to October 1, 2021.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for type 1 diabetes. The diabetes vaccine Diamyd^® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. Preparations for a confirmatory Phase III trial in the US and Europe are on-going, to start recruting patients later in 2021. A vaccine manufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd^®. Diamyd Medical also develops the GABA-based investigational drug Remygen^® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen^® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on August 18, 2021, 08.45 CET.